Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

ATTRV30M amyloidosis News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

BridgeBio Pharma's ATTR treatment, Attruby, is experiencing a robust launch, indicating strong market demand. In contrast, Alnylam has reduced its full-year sales forecast for Amvuttra, signaling potential challenges in the competitive landscape.

Following the Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals' therapy for transthyretin amyloid cardiomyopathy, five companies are reassessing their strategies in this space. The article provides insights into the current status of these contenders and their assets.

FDA Expands CRISPR Gene Therapy Casgevy to Children as Young as 2 with Sickle Cell Disease

Gene therapy for children with sickle cell disease approved by FDA

Not rare diseases news,news about your rare disease.

Earlier

BridgeBio Pharma's ATTR treatment, Attruby, is experiencing a robust launch, indicating strong market demand. In contrast, Alnylam has reduced its full-year sales forecast for Amvuttra, signaling potential challenges in the competitive landscape.

Following the Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals' therapy for transthyretin amyloid cardiomyopathy, five companies are reassessing their strategies in this space. The article provides insights into the current status of these contenders and their assets.

FDA Expands CRISPR Gene Therapy Casgevy to Children as Young as 2 with Sickle Cell Disease

Gene therapy for children with sickle cell disease approved by FDA

Not rare diseases news,
news about your rare disease.